{"entity":{"id":"nct05211895","kind":"trial","name":"A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC","aka":["PACIFIC-8"],"tldr":"A phase 3 trial testing Domvanalimab in non-small-cell lung cancer, active and no longer recruiting.","summary":"A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC is a phase 3 interventional study registered as NCT05211895, led by AstraZeneca with Arcus Biosciences, and active but no longer recruiting on the registry. Official title: A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab Plus Domvanalimab(AB154) in Participants With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease Has Not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy. Planned enrolment is 791 participants (actual). The study started in 2022-02-18 and primary completion is expected in 2026-08-10. No results have been posted on ClinicalTrials.gov.","status":"active","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT05211895","url":"https://clinicaltrials.gov/study/NCT05211895"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","stage-iii-unresectable-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["domvanalimab"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05211895","phase":"3","setting":"A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab Plus Domvanalimab(AB154) in Participants With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease Has Not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy","sponsor":"AstraZeneca","participation":[{"nct":"NCT05211895","source":"https://clinicaltrials.gov/study/NCT05211895","fetchedAt":"2026-10-07T16:53:37.286Z","studySha256":"1cb117b5880048d9c305e14f2f6d30c007e50d7b49d595d21a5fb4b69ff0aac2","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-08-28","leadSponsor":"AstraZeneca","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":791,"enrolmentType":"ACTUAL","siteCount":226,"recruitingSiteCount":0,"countries":["Belgium","Brazil","Canada","Chile","France","Germany","Greece","Hong Kong","Hungary","India","Italy","Japan","Malaysia","Mexico","Norway","Philippines","Poland","Romania","South Africa","South Korea","Spain","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","United States","Vietnam"]}],"started":"2022-02-18","startedType":"actual","enrolled":791,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05211895/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"stage-iii-unresectable-nsclc","kind":"cancer","name":"Unresectable stage III non-small-cell lung cancer","route":"/cancers/stage-iii-unresectable-nsclc/"}],"drug":[{"id":"domvanalimab","kind":"drug","name":"Domvanalimab","route":"/drugs/domvanalimab/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}